-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Treatment of CML in Pregnancy

Program: Education Program
Session: Beyond Routine Frontline Therapy of CML
Hematology Disease Topics & Pathways:
Non-Biological therapies, Chemotherapy, Chronic Myeloid Malignancies, Myeloid Malignancies
Sunday, December 11, 2022, 4:30 PM-5:45 PM

Jane F. Apperley, FRCP, FRCPath, MB

Hammersmith Hospital, Imperial College, London, ENG, United Kingdom

Disclosures: Apperley: Pfizer: Honoraria, Research Funding, Speakers Bureau; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.

OffLabel Disclosure: The drugs I will discuss are not meant to be used in pregnancy, but in clinical practice the patient is sometimes unaware they are pregnant and do not discontinue the drug promptly. In addition for patients with symptomatic diseases, there might be a clinical decision to use a drug for patient benefit as long as all are aware of the risks

<< Previous Presentation | Next Presentation